STAT1 and STAT3 Exhibit a Crosstalk and Are Associated with Increased Inflammation in Hepatocellular Carcinoma.

STAT1 STAT3 interleukin-6 liver cancer tumor microenvironment

Journal

Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829

Informations de publication

Date de publication:
23 Feb 2022
Historique:
received: 26 01 2022
revised: 18 02 2022
accepted: 21 02 2022
entrez: 10 3 2022
pubmed: 11 3 2022
medline: 11 3 2022
Statut: epublish

Résumé

Liver cancers, which are mostly hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA), are very aggressive tumors with poor prognosis. Therapeutic options with curative intent are largely limited to surgery and available systemic therapies show limited benefit. Signal transducer and activator of transcription 1 (STAT1) and 3 (STAT3) are key transcription factors activated by pro-inflammatory cytokines such as interferon-γ (IFN-γ) and interleukin-6 (IL-6). In this study, we combined in vitro cell culture experiments and immunohistochemical analyses of human HCC (

Identifiants

pubmed: 35267462
pii: cancers14051154
doi: 10.3390/cancers14051154
pmc: PMC8909292
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : German Cancer Aid
ID : 70113922
Organisme : Deutsche Forschungsgemeinschaft
ID : 314905040
Organisme : European Union
ID : E! 113707

Références

J Biol Chem. 2004 Oct 1;279(40):41679-85
pubmed: 15284232
Cancers (Basel). 2020 Mar 10;12(3):
pubmed: 32164265
Blood. 2006 Sep 1;108(5):1571-9
pubmed: 16645171
Semin Cell Dev Biol. 2008 Aug;19(4):351-9
pubmed: 18620071
Nat Rev Cancer. 2021 Sep;21(9):541-557
pubmed: 34326518
Sci Adv. 2021 Jan 22;7(4):
pubmed: 33523948
JAKSTAT. 2012 Apr 1;1(2):65-72
pubmed: 24058752
Am J Pathol. 2011 Aug;179(2):714-24
pubmed: 21684247
Br J Cancer. 2013 Nov 12;109(10):2665-74
pubmed: 24136146
Science. 2007 Jul 6;317(5834):121-4
pubmed: 17615358
J Clin Invest. 2011 Oct;121(10):3846-59
pubmed: 21926464
Future Oncol. 2020 May;16(15):975-989
pubmed: 32352320
BMC Cancer. 2019 Jan 15;19(1):72
pubmed: 30646854
Cancers (Basel). 2019 Aug 30;11(9):
pubmed: 31480382
Hepatology. 2016 Sep;64(3):828-42
pubmed: 27311882
Cancers (Basel). 2020 Jul 22;12(8):
pubmed: 32707820
J Clin Oncol. 2006 Dec 1;24(34):5373-80
pubmed: 17135638
Br J Cancer. 2015 Nov 3;113(9):1343-9
pubmed: 26461054
Nat Rev Gastroenterol Hepatol. 2020 Sep;17(9):557-588
pubmed: 32606456
Biochem Biophys Res Commun. 2017 Apr 29;486(2):239-244
pubmed: 28254435
Cancers (Basel). 2019 Dec 12;11(12):
pubmed: 31842362
Cancer Immunol Res. 2016 May;4(5):419-30
pubmed: 26968206
Hepatology. 2015 May;61(5):1627-42
pubmed: 25580681
Nat Med. 2013 Nov;19(11):1423-37
pubmed: 24202395
Hepatology. 2010 Dec;52(6):2023-33
pubmed: 20979053
J Hepatol. 2012 Aug;57(2):430-41
pubmed: 22504331
Nat Immunol. 2018 Mar;19(3):222-232
pubmed: 29379119
Nat Rev Cancer. 2009 Nov;9(11):798-809
pubmed: 19851315
Cell. 1999 Aug 6;98(3):295-303
pubmed: 10458605
N Engl J Med. 2019 Apr 11;380(15):1450-1462
pubmed: 30970190
Oncogene. 2019 Apr;38(15):2876-2884
pubmed: 30542122
Cancers (Basel). 2020 Dec 13;12(12):
pubmed: 33322216
Cancer Discov. 2021 Nov;11(11):2828-2845
pubmed: 34230008
Int J Exp Pathol. 2003 Dec;84(6):239-44
pubmed: 14748743
Proc Natl Acad Sci U S A. 2001 Jun 5;98(12):6680-5
pubmed: 11390995
Nat Med. 2004 Sep;10(9):942-9
pubmed: 15322536
J Immunol. 2014 May 15;192(10):4876-86
pubmed: 24711622
Immunity. 2018 Apr 17;48(4):812-830.e14
pubmed: 29628290
Semin Cancer Biol. 2020 Feb;60:41-56
pubmed: 31605750
Int J Cancer. 2009 Jun 15;124(12):2766-70
pubmed: 19267406
Int J Cancer. 2009 Nov 15;125(10):2264-9
pubmed: 19585572
J Cell Physiol. 2020 Dec;235(12):9457-9463
pubmed: 32401358
Nat Rev Drug Discov. 2019 Mar;18(3):197-218
pubmed: 30610226
Cell Mol Immunol. 2021 Jan;18(1):112-127
pubmed: 33235387
BMC Cancer. 2019 Dec 5;19(1):1191
pubmed: 31805897
Nat Rev Cancer. 2020 Apr;20(4):218-232
pubmed: 32024970
Br J Cancer. 2019 Jan;120(1):109-114
pubmed: 30377340
Cell Death Dis. 2020 Nov 30;11(11):1023
pubmed: 33257655
Nat Rev Dis Primers. 2021 Jan 21;7(1):6
pubmed: 33479224
Nat Immunol. 2013 Oct;14(10):1014-22
pubmed: 24048123
Nat Rev Dis Primers. 2016 Apr 14;2:16018
pubmed: 27158749

Auteurs

Carolin Ploeger (C)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Johannes Schreck (J)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.

Thorben Huth (T)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Angelika Fraas (A)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Thomas Albrecht (T)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.

Alphonse Charbel (A)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Junfang Ji (J)

The MOE Key Laboratory of Biosystems Homeostasis & Protection, Zhejiang Provincial Key Laboratory for Cancer Molecular Cell Biology, Life Sciences Institute, Zhejiang University, Hangzhou 310058, China.

Stephan Singer (S)

Institute of Pathology and Neuropathology, Eberhard-Karls University, 72076 Tuebingen, Germany.

Kai Breuhahn (K)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Stefan Pusch (S)

Department of Neuropathology, Institute of Pathology, University Hospital Heidelberg, 69120 Heidelberg, Germany.
Clinical Cooperation Unit Neuropathology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany.

Bruno Christian Köhler (BC)

Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.
Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Christoph Springfeld (C)

Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.
Department of Medical Oncology, National Center for Tumor Diseases, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Peter Schirmacher (P)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.

Arianeb Mehrabi (A)

Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.
Department of General, Visceral and Transplantation Surgery, Heidelberg University Hospital, 69120 Heidelberg, Germany.

Benjamin Goeppert (B)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.

Stephanie Roessler (S)

Institute of Pathology, Heidelberg University Hospital, 69120 Heidelberg, Germany.
Liver Cancer Center Heidelberg (LCCH), 69120 Heidelberg, Germany.

Classifications MeSH